Managing pediatric psoriasis: update on treatments and challenges—a review

References

• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
   PubMed Web of Science ®Google Scholar
• Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol. 2000;17(3):174–178.
   PubMed Web of Science ®Google Scholar
• Megna M, Napolitano M, Balato A, et al. Psoriasis in children: a review. Curr Pediatr Rev. 2015;11(1):10–26.
   PubMedGoogle Scholar
• Thorleifsdottir RH, Eysteinsdóttir JH, Olafsson JH, et al. Throat infections are associated with exacerbation in a substantial proportion of patients with chronic plaque psoriasis. Acta Derm Venereol. 2016;96(6):788–791.
   PubMed Web of Science ®Google Scholar
• Fortina AB, Bardazzi F, Berti S, et al. Treatment of severe psoriasis in children: recommendations of an Italian Expert Group. Eur J Pediatr. 2017;176(10):1339–1354.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. The voice of the patient. [updated 2016 November; cited 2021 May 22]. Available from: https://www.fda.gov/media/101758/download.
   Google Scholar
• US Food and Drug Administration. New pediatric labeling information database. [updated 2019 December 31; cited 2021 May 22]. Available from: https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?filter=psoriasis&sortColumn=1d&sd=labelingdatabase&page=1.
   Google Scholar
• Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241–251.
   PubMed Web of Science ®Google Scholar
• Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥6 to <12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183(4):664–672.
   PubMed Web of Science ®Google Scholar
• Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603.
   PubMed Web of Science ®Google Scholar
• Paller AS, Seyger MMB, Magariños GA, et al. Efficacy and safety of ixekizumab in a phase 3, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231–241.
   PubMed Web of Science ®Google Scholar
• Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021;35(4):938–947.
   PubMed Web of Science ®Google Scholar
• Magnolo N, Kingo K, Laquer V, et al. Secukinumab is highly efficacious and has a favorable safety profile in pediatric patients with moderate-to-severe plaque psoriasis. American Academy of Dermatology 2020; E-Congress 2020.
   Google Scholar
• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Sigurdardottir SL, Thorleifsdottir RH, Valdimarsson H, et al. The association of sore throat and psoriasis might be explained by histologically distinctive tonsils and increased expression of skin-homing molecules by tonsil T cells. Clin Exp Immunol. 2013;174(1):139–151.
   PubMed Web of Science ®Google Scholar
• Thomas J, Parimalam K. Treating pediatric plaque psoriasis: challenges and solutions. Pediatric Health Med Ther. 2016;7:25–38.
   PubMed Web of Science ®Google Scholar
• Silverberg NB. Pediatric psoriasis: an update. Ther Clin Risk Manag. 2009;5:849–856.
   PubMedGoogle Scholar
• Arese V, Albini P, Ibba F, et al. Juvenile psoriasis: an epidemiological study of 69 cases. G Ital Dermatol Venereol. 2018;153(4):469–472.
   PubMed Web of Science ®Google Scholar
• Pinson R, Sotoodian B, Fiorillo L. Psoriasis in children. Psoriasis. 2016;6:121–129.
   PubMedGoogle Scholar
• Mercy K, Kwasny M, Cordoro KM, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol. 2013;30(4):424–428.
   PubMed Web of Science ®Google Scholar
• Telfer NR, Chalmers RJ, Whale K, et al. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. 1992;128(1):39–42.
   PubMedGoogle Scholar
• Wu W, Debbaneh M, Moslehi H, et al. Tonsillectomy as a treatment for psoriasis: a review. J Dermatolog Treat. 2014;25(6):482–486.
   PubMed Web of Science ®Google Scholar
• Dupire G, Droitcourt C, Hughes C, et al. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst Rev. 2019;3:CD011571.
   PubMedGoogle Scholar
• Kwon HH, Na SJ, Jo SJ, et al. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. J Dermatol. 2012;39(3):260–264.
   PubMed Web of Science ®Google Scholar
• Tollefson MM, Crowson CS, McEvoy MT, et al. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979–987.
   PubMed Web of Science ®Google Scholar
• Wu Y, Lin Y, Liu HJ, et al. Childhood psoriasis: a study of 137 cases from Central China. World J Pediatr. 2010;6(3):260–264.
   PubMed Web of Science ®Google Scholar
• Bronckers IM, Bruins FM, Geel MJ, et al. Nail involvement as a predictor of disease severity in paediatric psoriasis: follow-up data from the Dutch Child CAPTURE registry. Acta Derm Venerol. 2019;99(2):152–157.
   PubMed Web of Science ®Google Scholar
• Bonigen J, Phan A, Hadj-Rabia S, et al. Impact of sex and age on the clinical and epidemiological aspects of childhood psoriasis: data from a French cross-sectional multicentre study. Ann Dermatol Venereol. 2016;143(5):354–363.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Hebert AA. Diagnosis of atopic dermatitis: mimics, overlaps, and complications. J Clin Med. 2015;4(5):884–917.
   PubMed Web of Science ®Google Scholar
• Hospach T, Glowatzki F, Blankenburg F, et al. Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents. Pediatr Rheumatol Online J. 2019;17(1):37.
   PubMedGoogle Scholar
• Minkis K, Aksentijevich I, Goldbach-Mansky R, et al. Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Arch Dermatol. 2012;148(6):747–752.
   PubMedGoogle Scholar
• Signa S, Campione E, Rusmini M, et al. Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of Ustekinumab. Pediatr Rheumatol Online J. 2019;17(1):38.
   PubMedGoogle Scholar
• Cowen EW, Goldbach-Mansky R. DIRA, DITRA, and new insights into pathways of skin inflammation: what's in a name? Arch Dermatol. 2012;148(3):381–384.
   PubMedGoogle Scholar
• Gómez-García F, Sanz-Cabanillas JL, Viguera-Guerra I, et al. Scoping review on use of drugs targeting interleukin 1 pathway in DIRA and DITRA. Dermatol Ther. 2018;8(4):539–556.
   Web of Science ®Google Scholar
• Hunjan MK, Maradit Kremers H, Lohse C, et al. Association between obesity and pediatric psoriasis. Pediatr Dermatol. 2018;35(5):e304–e305.
   PubMed Web of Science ®Google Scholar
• Paller AS, Mercy K, Kwasny MJ, et al. Association of pediatric psoriasis severity with excess and Central adiposity: an international cross-sectional study. JAMA Dermatol. 2013;149(2):166–176.
   PubMed Web of Science ®Google Scholar
• Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633–636.
   PubMed Web of Science ®Google Scholar
• Blegvad C, Egeberg A, Tind Nielsen TE, et al. Autoimmune disease in children and adolescents with psoriasis: a cross-sectional study in Denmark. Acta Derm Venereol. 2017;97(10):1225–1229.
   PubMed Web of Science ®Google Scholar
• Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med. 2017;17(1):65–70.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729–735.
   PubMed Web of Science ®Google Scholar
• Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265. e19.
   PubMed Web of Science ®Google Scholar
• Goenaga-Vázquez Y, Lauck KC, Hebert AA. Therapeutic challenges in managing pediatric psoriasis. Int J Womens Dermatol. 2021;7(3):314–318.
   PubMedGoogle Scholar
• Kim HO, Kang SY, Kim JC, et al. Pediatric psoriasis: from new insights into pathogenesis to updates on treatment. Biomedicines. 2021;9(8):940.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Megna M, Balato A, et al. Systemic treatment of pediatric psoriasis: a review. Dermatol Ther (Heidelb). 2016;6(2):125–142.
   PubMed Web of Science ®Google Scholar
• Katakam BK, Munisamy M, Rao TN, et al. Recommendations for management of childhood psoriasis. Indian Dermatol Online J. 2021;12(Suppl 1):S71–S85.
   PubMedGoogle Scholar
• Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci. 2018;33(1):173–180.
   PubMed Web of Science ®Google Scholar
• Calzavara-Pinton P, Zanca A, Arisi M, et al. Prevalence of phototherapy in the age of biologics. Dermatology. 2018;234(5–6):166–172.
   PubMed Web of Science ®Google Scholar
• Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2007;299(3):111–138.
   PubMed Web of Science ®Google Scholar
• Lara-Corrales I, Corrales IL, Ramnarine S, et al. Treatment of childhood psoriasis with phototherapy and photochemotherapy. Clin Med Insights Pediatr. 2013;7:25–33.
   PubMedGoogle Scholar
• Vangipuram R, Feldman SR. Ultraviolet phototherapy for cutaneous diseases: a concise review. Oral Dis. 2016;22(4):253–259.
   PubMed Web of Science ®Google Scholar
• Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: A systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):22–31.
   PubMed Web of Science ®Google Scholar
• Bhutani T, Kamangar F, Cordoro KM. Management of pediatric psoriasis. Pediatr Ann. 2012;41(1):e1-7–e7.
   PubMed Web of Science ®Google Scholar
• Shah KN. Diagnosis and treatment of pediatric psoriasis: current and future. Am J Clin Dermatol. 2013;14(3):195–213.
   PubMed Web of Science ®Google Scholar
• Wright NA, Piggott CD, Eichenfield LF. The role of biologics and other systemic agents in the treatment of pediatric psoriasis. Semin Cutan Med Surg. 2010;29(1):20–27.
   PubMed Web of Science ®Google Scholar
• Bronckers I, Seyger MMB, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153(11):1147–1157.
   PubMed Web of Science ®Google Scholar
• Bronckers I, Paller AS, West DP, et al. A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents. JAMA Dermatol. 2020;156(4):384–392.
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74(2):280–287. e1-3.
   PubMed Web of Science ®Google Scholar
• Cline A, Bartos GJ, Strowd LC, et al. Biologic treatment options for pediatric psoriasis and atopic dermatitis. Children. 2019;6(9):S33–S38.
   PubMedGoogle Scholar
• Thaçi D, Papp K, Marcoux D, et al. Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. Br J Dermatol. 2019;181(6):1177–1189.
   PubMed Web of Science ®Google Scholar
• Papp K, Thaci D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10089):40–49.
   PubMed Web of Science ®Google Scholar
• National Psoriasis Foundation. About psoriasis and psoriatic arthritis in children. [cited 2021 May 22]. https://www.psoriasis.org/children-with-psoriasis/.
   Google Scholar
• Faubion WA, Dubinsky M, Ruemmele FM, et al. Long-term efficacy and safety of adalimumab in pediatric patients with Crohn's disease. Inflamm Bowel Dis. 2017;23(3):453–460.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Gasink C, et al. Long-term efficacy and safety of Ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48(1):65–77.
   PubMed Web of Science ®Google Scholar
• Cosentyx® (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, December 2021.
   Google Scholar
• Taltz® (ixekizumab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company, November 2021.
   Google Scholar
• Deodhar A, Blanco R, Dokoupilová E, et al. Secukinumab improves signs and symptoms of non-radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study. Arthritis Rheumatol. 2021;73(1):110–120.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–2548.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599–611.
   PubMed Web of Science ®Google Scholar
• Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53–64.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258–270.
   PubMed Web of Science ®Google Scholar
• Bilgic A, Bilgic Ö, Akış HK, et al. Psychiatric symptoms and health-related quality of life in children and adolescents with psoriasis. Pediatr Dermatol. 2010;27(6):614–617.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Wu EQ, Guérin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651–657. e1-2.
   PubMed Web of Science ®Google Scholar
• de Jager ME, De Jong EM, Evers AW, et al. The burden of childhood psoriasis. Pediatr Dermatol. 2011;28(6):736–737.
   PubMed Web of Science ®Google Scholar
• Bruins FM, Bronckers I, Groenewoud HMM, et al. Association between quality of life and improvement in psoriasis severity and extent in pediatric patients. JAMA Dermatol. 2020;156(1):72–78.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Puig L, Mordin M, et al. Psoriasis patients with psoriasis area and severity index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Treat. 2017;28(6):492–499.
   PubMed Web of Science ®Google Scholar
• Strober B, Papp KA, Lebwohl M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75(1):77–82. e7.
   PubMed Web of Science ®Google Scholar
• Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645–648.
   PubMed Web of Science ®Google Scholar
• Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015;26(3):235–239.
   PubMed Web of Science ®Google Scholar
• Puig L, Thom H, Mollon P, et al. Clear or almost clear skin improves the quality of life in patients with moderate‐to‐severe psoriasis: a systematic review and meta‐analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213–220.
   PubMed Web of Science ®Google Scholar
• Torii H, Sato N, Yoshinari T, et al. Dramatic impact of a psoriasis area and severity index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. J Dermatol. 2012;39(3):253–259.
   PubMed Web of Science ®Google Scholar
• Edson-Heredia E, Banerjee S, Zhu B, et al. A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. J Eur Acad Dermatol Venereol. 2016;30(5):864–865.
   PubMed Web of Science ®Google Scholar
• Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432–470.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Paller AS, Tom WL, et al. Pediatric psoriasis: evolving perspectives. Pediatr Dermatol. 2018;35(2):170–181.
   PubMed Web of Science ®Google Scholar
• Schneeweiss MC, Huang JT, Wyss R, et al. Serious infection risk in children with psoriasis on systemic treatment: a propensity score-matched population-based study. J Am Acad Dermatol. 2020;82(6):1337–1345.
   PubMed Web of Science ®Google Scholar
• Makurvet FD. Biologics vs. small molecules: drug costs and patient access. Medicine Drug Discovery. 2021;9:100075.
   Google Scholar
• Wei SC. Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian Countries. Intest Res. 2016;14(3):218–223.
   PubMedGoogle Scholar
• Shah KN, Cortina S, Ernst MM, et al. Psoriasis in childhood: effective strategies to improve treatment adherence. Psoriasis. 2015;5:43–54.
   PubMedGoogle Scholar
• Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63(5):762–768.
   PubMed Web of Science ®Google Scholar